Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

Fig. 1

Patient disposition. Data from May 1, 2009, through March 31, 2016, were available. There were 975 unique CZP patients and 4625 unique other TNFi patients. aEligible patients with RA were ≥ 18 years of age, had at least one follow-up visit post-index drug initiation, and provided written informed consent prior to participation. bInitiations refer to the total number of TNFi initiated during the period of observation because patients may have used more than one TNFi during the study (e.g., if one patient switched from etanercept to CZP, both initiations would have been included in the analysis). cPropensity scores were calculated using a logistic regression model fitted with the following baseline covariates: age, sex, disease duration, CDAI at initiation, and TNFi line of therapy. RA rheumatoid arthritis, CZP certolizumab pegol, TNFi tumor necrosis factor inhibitor, IV intravenous, CDAI Clinical Disease Activity Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us